Asuragen Sets Sights on Pancreatic Cancer Screen Through TGen Collaboration

Terms of the arrangement, which marks Asuragen's first effort to develop an miRNA screen in a clinical setting, call for the partners to study blood samples from healthy individuals and patients with pancreatic abnormalities and pancreatic cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.